BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20551242)

  • 1. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
    Holmstock N; Mols R; Annaert P; Augustijns P
    Drug Metab Dispos; 2010 Sep; 38(9):1407-10. PubMed ID: 20551242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
    Holmstock N; Annaert P; Augustijns P
    Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
    Dahan A; Sabit H; Amidon GL
    Drug Metab Dispos; 2009 Oct; 37(10):2028-36. PubMed ID: 19589874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
    Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling.
    Mols R; Brouwers J; Schinkel AH; Annaert P; Augustijns P
    Drug Metab Dispos; 2009 Jun; 37(6):1334-7. PubMed ID: 19273528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.
    Richter M; Gyémánt N; Molnár J; Hilgeroth A
    Arch Pharm (Weinheim); 2006 Nov; 339(11):625-8. PubMed ID: 17048292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.
    Tempestilli M; Gentilotti E; Tommasi C; Nicastri E; Martini F; De Nardo P; Narciso P; Pucillo LP
    Int Immunopharmacol; 2013 Aug; 16(4):492-7. PubMed ID: 23707228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
    Cummins CL; Salphati L; Reid MJ; Benet LZ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
    Profit L; Eagling VA; Back DJ
    AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K; Trdan T; Trontelj J; Kristl A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site dependent intestinal absorption of darunavir and its interaction with ketoconazole.
    Stappaerts J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2013 Apr; 49(1):51-6. PubMed ID: 23395914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin.
    Huo X; Liu Q; Wang C; Meng Q; Sun H; Peng J; Ma X; Liu K
    Eur J Pharm Sci; 2013 Nov; 50(3-4):420-8. PubMed ID: 23981338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents.
    Garner CE; Solon E; Lai CM; Lin J; Luo G; Jones K; Duan J; Decicco CP; Maduskuie T; Mercer SE; Gan LS; Qian M; Prakash S; Shen HS; Lee FW
    Drug Metab Dispos; 2008 Jun; 36(6):1102-10. PubMed ID: 18347085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
    Ward KW; Azzarano LM
    J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
    Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
    J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
    Zastre JA; Chan GN; Ronaldson PT; Ramaswamy M; Couraud PO; Romero IA; Weksler B; Bendayan M; Bendayan R
    J Neurosci Res; 2009 Mar; 87(4):1023-36. PubMed ID: 18855943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
    Dufek MB; Knight BM; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.